One of the most anticipated and largest international summits of pulmonology, the European Respiratory Society’s (ERS) International Congress, is scheduled to take place on September 6-10, 2014. During this event, Insmed Incorporated will present data on their latest advancements in inhalation modalities for respiratory diseases. This year’s venue for the event will be held at the Internationales Congress Center München in Munich, Germany.
While most of the event will revolve around how the company’s new therapies can benefit patients diagnosed with respiratory infections, pulmonary hypertension (PAH), and chronic obstructive pulmonary diseases (COPD), treatment of cystic fibrosis (CF) will also be part of Insmed’s presentation.
Cystic Fibrosis is a hereditary and chronic disorder of the mucous glands, which causes the production of large amounts of very thick, obstructive mucus. This mucus may serve as an ideal medium for pathogenic microorganisms to proliferate in, rendering CF patients highly prone to respiratory infections and impaired lung function, which become quite difficult to manage.
The company will be presenting its flagship inhalation product, ARIKAYCE (liposomal amikacin), which ideally should be administered through a currently experimental eFlow Nebulizer System from PARI Pharma GmbH. ARIKAYCE is indicated for treatment of nontuberculous mycobacteria respiratory infections, and Pseudomonas aeruginosa infections in CF patients.
A presentation entitled, “Interim data from a long-term safety, tolerability and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection” is scheduled for Tuesday, September 9, 2014, at 10:45 a.m. – 12:45 p.m. The open forum will commence at 11:15 a.m.
More inhalation products and related studies are set to be presented during the 5-day summit. To view the complete schedule of presentations, click here.
For more information about Insmed Inc.’s highly promising liposomal amikacin formulation, and as a primer for the event, read on about how ARIKAYCE is proving to be an effective treatment option for CF patients fighting an opportunistic respiratory infection.